Introduction {#sec1}
============

Every year, approximately 15 million babies (10% of all births worldwide) are born preterm, defined as delivery before 37 weeks of gestation \[[@bib1]\]. Preterm birth is the leading cause of infant mortality \[[@bib4]\], and those born prematurely have increased lifelong risks of adverse health outcomes including cognitive impairment, cardiovascular disease, and chronic pulmonary disease \[[@bib5]\]. In approximately one third of preterm births, labor is induced or cesarean section is performed because of maternal or fetal complications such as preeclampsia, intrauterine growth restriction, or fetal distress. However, the majority of preterm births are spontaneous, brought about by preterm labor (uterine contractions leading to cervical change and delivery) or preterm premature rupture of fetal membranes (PPROM) \[[@bib6], [@bib7]\]. Unfortunately, the multiple causes of preterm labor have not been fully determined, and we have limited ability to predict or prevent preterm birth \[[@bib8]\].

To address these limitations, researchers have developed various mouse models of preterm birth \[[@bib11]\]. Mice are useful for studying the timing of birth because they have a short gestation, can easily be genetically manipulated, are inexpensive, and can be studied in large numbers \[[@bib12]\]. Additionally, key components of the labor and delivery process are conserved between mice and humans. For example, the expression levels of several proteins that activate uterine contractions including prostaglandins, oxytocin, and connexin-43 are elevated at term in both species \[[@bib11], [@bib13]\]. Finally, parturition timing is somewhat variable in both humans, in whom 90% of births occur between 37 and 42 weeks of gestation, and mice, in which gestation lengths vary between strains from 19 to 21 days \[[@bib16]\].

Despite these similarities, three key physiological differences between human and mouse pregnancy are worth mentioning. First, whereas women typically have singleton pregnancies \[[@bib17]\] within a single uterine cavity, mice commonly have 4 to 10 pups per litter (depending on strain) \[[@bib16]\] within two uterine horns. This can complicate comparisons between species because women carrying multiple pregnancies are at increased risk for preterm birth \[[@bib18]\]. Second, although progesterone is required to maintain pregnancy and is initially produced by the corpus luteum in both humans and mice, its production thereafter is regulated differently in the two species. In humans, the placenta takes over progesterone production after gestational week 7 or 8, and progesterone levels rise fairly continuously until the end of pregnancy \[[@bib19], [@bib20]\]. At the end of human pregnancy, a shift in progesterone receptor isoform expression and local increases in progesterone metabolism \[[@bib21], [@bib22]\] result in a functional withdrawal of the "pregnancy-maintaining" hormone. In mice, progesterone synthesis and levels decrease while local progesterone metabolism \[[@bib23]\] increases dramatically in the last two days of pregnancy, facilitating the onset of parturition. Third, although estrogens inhibit uterine quiescence and promote cervical ripening after progesterone action decreases (by promoting production of uterotonins and contraction-associated proteins, including: connexin-43, oxytocin receptor, cyclooxygenase 2, and prostaglandin F receptor) in both humans and mice, estrogen is regulated differently in the two species. In humans, circulating estrogens, derived from the ovary and placenta, are high throughout gestation. In mice, estrogens are synthesized by the ovary at low levels in the first half of pregnancy and then markedly increase in the latter half of gestation.

As we detail in this review, "preterm birth" is loosely defined for mice, and our field lacks clear, accepted guidelines for conducting experiments and reporting results. Thus, we cannot easily compare mouse studies and use their results to improve our ability to predict and prevent preterm birth in women. This review seeks to fill this gap by describing mouse preterm birth models published in the literature and the ways in which they aim to represent the human condition. Additionally, we discuss experimental differences leading to inconsistent definitions of preterm birth in mice and propose criteria to provide more uniform assessment of mouse models. Finally, we suggest that investigators should assess and report the developmental status (mature or premature) of offspring. Toward this end, we describe promising fetal developmental markers that can be used to distinguish between mature and premature pups.

Mouse models of preterm birth {#sec2}
=============================

Here, we review the major classes of mouse preterm birth models, categorized by pathologic state. Representative examples are provided in Table [1](#tbl1){ref-type="table"}.

###### 

Published preterm birth mouse models.

                                                                                                                                                                                                                                                       Stimulant                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ------------------------------- --------------------------------------------------- ---------------------------------------------------- ---------------- --------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------------------- ------------------------- ----------------------------------------------------------------------------------------- ---------------
  Infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                  N/A                                                 CD-1                                                 19--20           ND                          Vaginal plug; dpc not defined                                  *E. coli* 2 -- 10 × 10^5^                                                                    IU/IP                                                                                                                   14.5 dpc                               Within 48 h                                                   ND                        None                                                                                      \[[@bib31]\]
                                  N/A                                                 C3H/HeN x C3H/HeN C3H/HeN x B6D2F1 BALB/c x B6D2F1   19--20           ND                          Vaginal plug and spermatozoa in vaginal smear at 0.0 dpc       LPS serotype 055:B5                                                                          IP - 50 or 100 μg/kg (one injection) Or 50 μg/kg (two injections)                                                       12, 15, or 17 dpc                      \<19 dpc                                                      19--20 dpc                None                                                                                      \[[@bib32]\]
                                  N/A                                                 CD-1                                                 ND               ND                          Vaginal plug at 0.0 dpc                                        LPS serotypes 0111:B4, 055:B5, 0127:B8\*, and 0128:B12                                       IU 20 μg in 25 μl                                                                                                       16 dpc                                 36 h postinjection                                            60 ± 15 h postinjection   LPS 0111:B4 none 055:B5 80% 0127:B8 95% 0128:B12 100%                                     \[[@bib33]\]
                                  TLR-4 mutant                                        CD-1 C3H/HeJ                                         19--20           Timed pregnant (supplier)   ND                                                             LPS serotype L2280 (CD-1) L2880 and L4525 for TLR-4 mutant                                   IU 250 μg/mouse (Sigma)                                                                                                 15 dpc                                 At least 1 pup born \< 48 h after LPS admin                   19--20 dpc                None                                                                                      \[[@bib35]\]
                                  *C5aR−/−*                                           129S4/SvJae                                                           ND                          Vaginal plug at 0 dpc                                          No treatment, LPS serotype 055:B5 or RU486                                                   250 μg LPS intravaginally SC 150 μg RU486 dissolved in DMSO                                                             15 dpc                                 Within 48 h postinjection                                     20--21 dpc                ND                                                                                        \[[@bib36]\]
                                  N/A                                                 CD-1                                                 19--20           ND                          Vaginal plug, dpc not defined                                  TLR-2 ligand lipoteichoic acid, peptidoglycan, or TLR-3 ligand polyinosinic:cytidylic acid   IU and IP                                                                                                               14.5 or 15.5 dpc                       At least 1 pup born or in lower vagina \<48 h after surgery   19--20 dpc                None                                                                                      \[[@bib37]\]
                                  N/A                                                 C3H/HeNCrj X Crj: B6D2F1                             19--20           ND                          Vaginal plug and spermatozoa in the vaginal smear at 0.0 dpc   Lipoteichoic acid                                                                            IP 12.5--75 mg/kg single dose or repeated doses at 3h intervals                                                         15 dpc 17 dpc                          \<19.0 dpc                                                    19--20 dpc                None with doses given on 15 dpc 100% viable with doses given on 17 dpc                    \[[@bib38]\]
                                  N/A                                                 C57BL/6                                              19.5 ± 0.5       ND                          ND                                                             iE-DAP                                                                                       IP 500, 750, or 1000 μg in 200 μl PBS                                                                                   14.5 dpc                               Delivery within 24 h postinjection                            ND                        ND                                                                                        \[[@bib39]\]
                                  N/A                                                 CD-1                                                 ND               Timed pregnant (supplier)   ND                                                             Heat-killed GBS                                                                              IP or IU 10^9^ in 100 μl                                                                                                14.5 dpc                               Within 48 h postinjection                                     ND                        ND                                                                                        \[[@bib42]\]
                                  N/A                                                 C3H/HeN                                              19--20           ND                          Vaginal plug at 0.0 dpc                                        Ureaplasmal outer membrane lipoprotein                                                       IU 15 μg                                                                                                                14.0 dpc                               Within 48 h                                                   ND                        ND                                                                                        \[[@bib45]\]
                                  N/A                                                 BALB/c (*H-2^[d](#tb1fn4){ref-type="table-fn"}^)*    19--20           Overnight                   Vaginal plug at 0 dpc                                          *Chlamydia trachomatis* mouse pneumonitis biovar (strain Nigg II)                            10^1^ to 10^7^ inclusion-forming units in 20 μl of 0.2 M sucrose--20 mM sodium phosphate (pH 7.2)--5 mM glutamic acid   5 dpc                                  ND                                                            19.3                      Maternal cannibalism precluded evaluation                                                 \[[@bib47]\]
                                  N/A                                                 C3H/HeJ                                              20               Timed-pregnant (supplier)   ND                                                             *E. coli* Dr^+^ IH11128 and Dr14                                                             Urethral catheterization into urinary bladder                                                                           7 dpc                                  On or before 18 dpc                                           ND                        53.6%                                                                                     \[[@bib50]\]
                                  N/A                                                 C57Bl/6J                                             20.45            ND                          Vaginal plug at 0.0 dpc                                        W83 strain of *P. gingivalis*                                                                10^8^ CFU                                                                                                               6 weeks before mating                  17--18.25 dpc                                                 Delivery                  ND                                                                                        \[[@bib55]\]
                                  Faah--/--; Cnr--/--                                 ND                                                   ∼19.8            ND                          Vaginal plug at 1.0 dpc                                        LPS 0111:B4                                                                                  IP 25 μg                                                                                                                16.0 dpc                               Before 19 dpc                                                 ∼19.8 dpc                 None                                                                                      \[[@bib139]\]
                                  N/A                                                 Kunming (derived from Swiss Webster)                 ND               Overnight                   Vaginal plug at 0.0 dpc                                        LPS serotype 0127                                                                            IP 150 μg/kg                                                                                                            15.5 dpc                               15.5--17 dpc                                                  18.0--20.0 dpc            47%[^d^](#tb1fn4){ref-type="table-fn"}                                                    \[[@bib140]\]
                                  N/A                                                 CD-1                                                 19--20           Overnight                   Vaginal plug at 0.0 dpc                                        LPS serotype 0111                                                                            IU 10 μg                                                                                                                16.0 dpc                               12.7 ± 7 h                                                    ND                        14.6 ± 31% viable, but included deliveries 25--37 h after LPS                             \[[@bib141]\]
                                  N/A                                                 C57BL/6                                              19.5 ± 0.5       Overnight                   Vaginal plug at 0.5 dpc                                        LPS                                                                                          IP 0.5 μg                                                                                                               16.5 dpc                               Before 18.0 dpc                                               ND                        2.3 fetuses per dam, may include term deliveries                                          \[[@bib142]\]
                                  N/A                                                 C57BL/6                                              19.5 ± 0.5       ND                          Vaginal plug at 0.5 dpc                                        LPS serotype 0111:B4                                                                         IA 100 ng/sac                                                                                                           16.5 dpc                               Before 18.0 dpc                                               ND                        ND                                                                                        \[[@bib143]\]
                                  Uterine-specific p53 knockout                       FVB/129                                              ND C57BL/6-129   Overnight                   Vaginal plug at 1.0 dpc                                        LPS                                                                                          IP 10 μg/ml                                                                                                             16.0 dpc                               Before 19 dpc                                                 ND                        28% w/o LPS; 0% with LPS                                                                  \[[@bib84]\]
  Inflammation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                  N/A                                                 C3H/Hel                                              20--21           Timed pregnant (supplier)   ND                                                             Interleukin-1                                                                                SC                                                                                                                      15--17 dpc                             Within 24 h                                                   20--22 dpc                ND                                                                                        \[[@bib61]\]
                                  N/A                                                 C57BL/6                                              19.5 ± 0.5       Overnight                   Vaginal plug at 0.5 dpc                                        High-mobility group box-1                                                                    IA 9 ng                                                                                                                 14.5 dpc                               17.35 dpc                                                     19.5 ± 0.5 dpc            ∼85.4% viability; 60.9 ± 11.7% pup death by 1 week of age                                 \[[@bib64]\]
  Cesarean                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                  N/A                                                 CD-1                                                 20               Overnight                   Vaginal plug at 1.0 dpc                                        Cesarean                                                                                     NA                                                                                                                      NA                                     On 18 or 19 dpc                                               20 dpc                    0% (18 dpc) 87.8% (19 dpc)                                                                \[[@bib65]\]
                                  N/A                                                 CD-1                                                 19--20           Timed pregnant (supplier)   ND                                                             Cesarean                                                                                     NA                                                                                                                      NA                                     1 or 2 days before term                                       Delivery                  100%                                                                                      \[[@bib144]\]
  PPROM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                  N/A                                                 C57BL/6                                              19.5 ± 0.5       Pair mated (5 h)            ND                                                             Fetal fibronectin                                                                            Between fetal membranes and uterine lining (100--200 μg/ml)                                                             17.0 dpc                               \<18.5 dpc                                                    19 dpc                    20%                                                                                       \[[@bib70]\]
                                  Biglycan and Decorin double knockout                C3H                                                  19.5             Overnight                   Vaginal plug at 0.0 dpc                                        NA                                                                                           NA                                                                                                                      NA                                     Before 18.0 dpc                                               19.5 dpc                  0%                                                                                        \[[@bib67]\]
  Early progesterone withdrawal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                  N/A                                                 C3H/HeN                                              19--20           Overnight                   Vaginal plug at 1.0 dpc                                        Mifepristone (RU486)                                                                         SC 50--250 μg                                                                                                           12--14 dpc                             Within 18 h                                                   19--20 dpc                100%                                                                                      \[[@bib75]\]
  Prostaglandins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                  N/A                                                 C3H/HeN                                              19--20           Timed Pregnant (supplier)   ND                                                             Prostaglandin F~2α~                                                                          IP 20 μg                                                                                                                16 dpc                                 Within 24 h                                                   \<18 dpc                  ND                                                                                        \[[@bib82]\]
                                  15-hydroxy- prostaglandin dehydrogenase hypomorph   C57BL/6-129/SvJ                                      ∼19.3            ND                          Vaginal plug, dpc not defined                                  NA                                                                                           NA                                                                                                                      NA                                     Shorter gestation than control                                ∼19.3 dpc                 Equivalent to term                                                                        \[[@bib80]\]
  Uterine quiescence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                  N/A                                                 CD-1                                                 19               Timed pregnant (supplier)   ND                                                             Tunicamycin                                                                                  IP 0--1 mg/kg                                                                                                           15 dpc                                 18--32 h postinjection                                        19 dpc                    Nonviable neonates at 16 and 17 dpc                                                       \[[@bib89]\]
  Endocannabinoid signaling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                  CB1 knockout                                        C57BL/6J/129                                         ∼20.1            Overnight                   Vaginal plug at 1.0 dpc                                        NA                                                                                           NA                                                                                                                      NA                                     Before ∼19.5 dpc                                              ∼20.1 dpc                 Yes                                                                                       \[[@bib99]\]
  Hyperhomocysteinemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                  CBS knockout                                        C57BL/6J                                             20.0 ± 0.2       Overnight                   Vaginal plug at 0.5 dpc                                        NA                                                                                           NA                                                                                                                      NA                                     At 16.6 ± 0.1 dpc                                             20.0 ± 0.2 dpc            Yes                                                                                       \[[@bib102]\]
  Environmental effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                  N/A                                                 C57BL/6                                              19.5 ± 0.5       Overnight                   Vaginal plug at 0.5 dpc                                        2,3,7,8-tetrachlo- rodibenzo-p-dioxin (dioxin)                                               Mother was gavaged 10 μg/kg; no exposure as adult                                                                       In utero at 15.5 dpc, none as adult    24 h before term                                              20 dpc                    Pups born preterm appeared viable at birth, died within 24 h Pups born at term survived   \[[@bib105]\]
                                  N/A                                                 BL6C3F1                                              20.3 ± 0.2       Two days                    First day of pairing defined as 0.0 dpc                        Cigarette smoke diluted 90%                                                                  Inhalation                                                                                                              2--18 dpc                              At 19.6 ± 0.2 dpc                                             20.3 ± 0.2 dpc            Yes                                                                                       \[[@bib145]\]
  Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                  N/A                                                 CD-1                                                 19--20           Overnight                   Vaginal plug at 0 dpc                                          L-arginine analog N^G^-nitro-L-arginine methyl ester (L-NAME)                                SC 0 (vehicle), 40, 70, or 100 mg L-NAME/kg in 10 ml/kg body weight                                                     15.5 dpc and 16 dpc                    Before 18 dpc                                                 18--19.5 dpc              Maternal cannibalism precluded evaluation                                                 \[[@bib107]\]
                                  N/A                                                 CD-1                                                 19--20           Overnight                   Vaginal plug at 0 dpc                                          Methylene Blue                                                                               SC 5, 30, 50, 60 or 85 mg/kg in 5 ml/kgb                                                                                15.5 dpc and 16 dpc                    Before 18 dpc                                                 18--19.5                  Appeared viable but maternal cannibalism precluded evaluation                             \[[@bib108]\]
                                  N/A                                                 ICR (CD-1)                                           19--20           Overnight                   Vaginal plug at 0.5 dpc                                        Surfactant protein (SP)-A                                                                    IA 3 μg in 50 μl per sac                                                                                                15 dpc                                 ND                                                            19 dpc                    ND                                                                                        \[[@bib109]\]
                                  N/A                                                 BALB/C                                               20.2 ± 0.1       Overnight                   Vaginal plug at 0 dpc                                          Neuromedin B                                                                                 IP 30, 90, or 150 μg/kg of NMB                                                                                          18 dpc and 19 dpc at 1400 and 1800 h   ND                                                            ND                        ND                                                                                        \[[@bib110]\]
                                  N/A                                                 C57Bl/6J                                             19.5 ± 0.5       ND                          Vaginal plug at 1 dpc                                          Alcohol                                                                                      Intra-gastric 6 g/kg                                                                                                    17 dpc or 18 dpc                       18.9 ± 0.1 dpc 19.5 ± 0.2 dpc                                 20.1 ± 0.1                ND                                                                                        \[[@bib111]\]

^a^As discussed by author or determined by \[[@bib16]\]

^b^dpc, days postcoital

^c^IA, intraamniotic; IP, intraperitoneal; IU, intruterine; SC, subcutaneous

^d^includes term deliveries

NA, not applicable

ND, not discussed

LPS, Lipopolysaccharide

Infection {#sec2-1}
---------

Multiple studies have implicated activation of inflammatory pathways in the process of normal uncomplicated labor (as reviewed in \[[@bib24]\]). However, early initiation of the inflammatory pathway by infection contributes to between 25% and 40% of all human preterm births \[[@bib25]\]. Infections can develop in two major ways. Chorioamnionitis or intrauterine infection can arise systemically, or commensal bacteria can ascend from the female genital tract. Several mouse models of infection-induced preterm birth have been developed \[[@bib28], [@bib29]\], most commonly using *Escherichia coli* or the toxic component on the surface of gram-negative bacteria, lipopolysaccharide (LPS). Other bacteria associated with increased risk of preterm birth in humans, and therefore studied in mice, include *Ureaplasma*, *Chlamydia trachomatis*, Group B streptococcus (GBS; *Streptococcus agalactiae*), and *Porphyromonas gingivalis*. To mimic local infection, investigators have performed intrauterine, intraamniotic, or intraperitoneal injections with live or heat-killed bacteria. To simulate systemic infection, they administer injections intraperitoneally, and to mimic ascending infections, they inject bacteria vaginally or via the intrauterine route \[[@bib30]\].

Mice injected with live or heat-killed *E. coli* or LPS on 14.5--15.5 days post coitus (dpc) delivered within 7--48 h, depending on the route of administration and LPS serotype used. Specific *E. coli*-derived LPS serotypes differentially activated proinflammatory responses, caused mice to deliver at different times postinjection, and were associated with varying levels of offspring survival \[[@bib33]\]. Both *E. coli* and LPS stimulate the Toll-like receptor (TLR)-4 in the uterus and activate an inflammatory cascade \[[@bib34]\]. Further investigation of localized intrauterine inflammation revealed that the TLR-4 pathway stimulated platelet activating factor, an important mediator of the signal transduction pathway that led to inflammatory-induced preterm delivery \[[@bib35]\]. In addition, LPS administered vaginally has been shown to work through the complement receptor C5a, affecting cervical remodeling by increasing metalloproteinase-9 activity and collagen degradation \[[@bib36]\].

Intrauterine injections of lipoteichoic acid (an anionic polymer on the surface of gram-positive bacteria), peptidoglycan (also a major component on the surface of gram-positive bacteria), or polyinosinic acid (an analog of viral double-stranded RNA) caused mice to deliver preterm by mechanisms similar to that of LPS, albeit through different TLRs \[[@bib37], [@bib38]\]. Specifically, administration of the bacterial peptidoglycan-derived peptide γ-D-glutamyl-meso-diaminopimelic acid, an agonist of the pattern recognition receptor Nod-1, caused mouse preterm birth via maternal-fetal inflammation \[[@bib39]\].

In humans, GBS is the leading cause of perinatal infection, and maternal GBS infection increases the risk for preterm birth \[[@bib40], [@bib41]\]. To model this etiology, Hirsch and colleagues injected pregnant mice (intraperitoneal or intrauterine) with 10^9^ heat-killed GBS on 14.5 dpc \[[@bib42]\]. In this model, approximately 86% of pregnant mice delivered within 18 h and showed signs of placental and membrane apoptosis. In another model, 75% of mice that were vaginally colonized with GBS on 16 dpc delivered preterm. However, 0% of mothers that were vaccinated with GBS before mating delivered preterm, and their pups had higher survival rates and lower levels of neonatal GBS infection than those from unvaccinated mothers \[[@bib42]\].

Another bacterial genus that commonly infects the uterus and causes preterm birth in humans is *Ureaplasma*, a member of the *Mycoplasmataceae* family \[[@bib43]\]. Additionally, *Ureaplasma* is the most frequently isolated bacterial pathogen in cases of chorioamnionitis \[[@bib44]\]. One group reported that injecting a diacylated lipopeptide derived from *Ureaplasma parvum* into the uterus of pregnant mice on 15 dpc resulted in preterm delivery, although the day of delivery was not defined. This work revealed that *Ureaplasma* likely induced preterm birth by binding to TLR-2 and activating the NF-κB inflammatory cascade \[[@bib45]\].

The pathogen *Chlamydia trachomatis* is the most prevalent sexually transmitted bacteria and is associated with preterm delivery \[[@bib46]\]. Mice infected with 10^5^--10^7^ inclusion-forming units (IFU) of *C. trachomatis* delivered on 15.8--16.4 dpc, whereas those infected with 10^1^--10^4^ IFU delivered on 19.5--19.6 dpc, and those that received vehicle or no treatment delivered had a mean gestation length of 19.3 dpc \[[@bib47]\]. Acute to severe inflammation and *C. trachomatis* inclusions were noted in the maternal uterine wall, endometrium, and fetal membranes but were absent in the amnion and fetal organs.

Urinary tract infections, most commonly caused by *E. coli* \[[@bib48]\], have long been known to be associated with increased risk for preterm birth in humans \[[@bib49]\]. To model this etiology, mice were infected with *E. coli* via urethral catheterization into the urinary bladder on 7 dpc. Nearly 90% of those infected with bacteria expressing the Dr adhesin delivered between 11 and 18 dpc \[[@bib50]\], whereas only 10% of those infected with *E. coli* not expressing this Dr adhesin delivered preterm. *Escherichia coli* expressing Dr adhesin were able to colonize the kidneys and spleen of the mothers and transfer through the placenta to the fetuses, causing reduced fetal weight and poor organ development.

Maternal infections distant from the uterus have also been implicated in preterm birth. For example, some data suggest that maternal periodontal disease increases the risk of preterm birth by sevenfold \[[@bib51]\]. Periodontal pathogens are capable of entering the bloodstream and spreading throughout the body and have been detected in the amniotic fluid \[[@bib52], [@bib53]\]. Moreover, *P. gingivalis* antigens have been detected in the placentas of women with chorioamnionitis \[[@bib54]\]. In a mouse model of periodontal infection, *P. gingivalis* was injected into the first molar chambers of female mice 6 weeks before mating. Infected mice delivered 2 days earlier and had higher circulating levels of the proinflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-17, IL-6, and IL-1B than noninfected mice. Additionally, the bacteria were found in the placentas, and the mothers showed features of PPROM and placental abruption \[[@bib55]\].

Inflammation {#sec2-2}
------------

Inflammation in the absence of overt infection is a common etiology of preterm birth. In fact, sterile intra-amniotic inflammation is associated with ∼26% of all preterm deliveries and is more common in early than in late preterm deliveries \[[@bib56], [@bib57]\]. An important contributor in sterile intra-amniotic inflammation is the cytokine IL-1, which is expressed in the human decidua, promotes prostaglandin production, and is detected at high levels in the uterus of women who deliver preterm \[[@bib58]\]. IL-1 stimulates preterm birth in rabbits and nonhuman primates \[[@bib59], [@bib60]\]. To model this in mice, researchers injected pregnant mice with IL-1 three times between 15 and 17 dpc, leading to delivery within 24 h \[[@bib61]\]. Other important players in sterile intra-amniotic inflammation are danger signals, such as damage-associated molecular pattern molecules and alarmins, which, upon stimulation by cellular stress and necrosis, activate the innate immune system \[[@bib62]\]. One such alarmin, high mobility group box 1 (HMGB1), is increased in women with intra-amniotic inflammation \[[@bib63]\]. To model this etiology of preterm birth, researchers injected HMGB1 into the amniotic sacs of fetuses on 14.5 dpc; 57% of the injected mice delivered by 17.5 dpc, whereas all of the controls delivered at full term (19.5 dpc) \[[@bib64]\].

Cesarean section {#sec2-3}
----------------

To benefit maternal or fetal health, preterm cesarean delivery may be performed after either medically indicated or spontaneous preterm labor. To investigate the effect of cesarean delivery on fetal development and mortality, researchers surgically removed mouse fetuses before the normal delivery date and found that pups of the strain CD-1 could only be resuscitated when delivered on 19 or 20 dpc (20 dpc was the normal delivery time for this strain in their colony) \[[@bib65]\], indicating that mice cannot survive outside the uterus if birth occurs more than 1 day preterm.

Preterm premature rupture of membranes {#sec2-4}
--------------------------------------

In women, PPROM is a significant pregnancy complication. In this condition, the chorioamniotic membrane surrounding the fetus ruptures before 37 weeks of pregnancy, breaching the barrier between the extrauterine and intrauterine environment, allowing the amniotic fluid to leak out, and increasing the risk for infection and preterm birth. PPROM can be caused by infection, overdistension of the uterus and amniotic sac (such as in multiple pregnancies), trauma, or genetic disorders. For example, women with Ehlers-Danlos syndrome carry mutations in the genes encoding proteins involved in assembly of collagen and elastic fibers and are at increased risk of PPROM, cervical insufficiency, uterine rupture, and delivering an intrauterine growth-restricted fetus \[[@bib66]\]. C3H mice with targeted mutations in genes encoding specific proteoglycans, such as biglycan and decorin, displayed an Ehlers-Danlos-like phenotype that included reduced litter size and intrauterine growth restriction. Additionally, despite lacking an inflammatory response, these mice delivered before 18.0 dpc, with 43% delivering by 17.0 dpc, and none of the fetuses survived \[[@bib67]\].

The extracellular matrix glycoprotein fetal fibronectin (fFN) is part of the amniotic membranes, and detection of fFN in cervical and vaginal fluid has been associated with an increased risk for spontaneous preterm birth. However, few patients with a positive fFN result will actually deliver early \[[@bib10], [@bib68], [@bib69]\]. In mice, injection of fFN at 17.0 dpc causes preterm delivery within 12--36 h, likely via PPROM induced by activation of matrix metalloproteinases and cyclooxygenase-2 \[[@bib70]\]. Likewise, injecting mice with thrombin at 17.0 dpc increased levels of matrix metalloproteinases and cyclooxygenase-2 and caused delivery of non-viable pups within 24 h \[[@bib70]\].

Early progesterone withdrawal {#sec2-5}
-----------------------------

A successful pregnancy requires uterine smooth muscle quiescence before parturition/labor. During gestation, progesterone is one of the predominant hormones produced by the placenta and is responsible for keeping the myometrium in a quiescent state. Progesterone levels remain high throughout human pregnancy, but women undergo a "functional" progesterone withdrawal at the end of pregnancy. This reduction in progesterone action is mediated by alterations in the ratio of progesterone receptor A to progesterone receptor B \[[@bib73]\], changes in cofactor expression, and/or local metabolism of progesterone, thereby allowing contractions to initiate and the cervix to ripen \[[@bib74]\]. Consistent with this idea, the anti-progesterone and anti-glucocorticoid drug Mifepristone, also known as RU486, induces uterine contractions and cervical ripening. To model early progesterone withdrawal, investigators injected mice with RU486 on 12--14 dpc, resulting in delivery within 18 h in ∼84% of C3H/HeN mice. Although this study reported that pups were born alive, postnatal pup survival was not discussed \[[@bib75]\]. RU486-induced premature cervical ripening in Blk6/129SvEv mice was reported to be similar to term ripening and distinct from LPS-induced premature ripening in terms of gene expression, immune cell populations, and microstructural reorganization of collagen \[[@bib76], [@bib77]\]. In other reports, RU486 was suggested to promote cervical remodeling by activating the complement receptor C5a \[[@bib36]\].

Prostaglandins {#sec2-6}
--------------

At the end of human pregnancy, levels of the prostaglandins PGE~2~ and PGF~2α~ increase, bind to receptors on the uterus, and promote contractions. Clinically, PGE~1~ (misoprostol) is used to induce both uterine contractions and cervical ripening (effacement or thinning). As an alternative to giving women exogenous prostaglandins, mechanical compression of the cervix promotes local release of endogenous prostaglandins \[[@bib78], [@bib79]\]. To model excess prostaglandin activity in mice, researchers created a C57BL/6-129/SvJ mouse line with a hypomorphic mutation in hydroxyprostaglandin dehydrogenase (PGDH), which hydrolyzes prostaglandins. These mice had elevated levels of PGE~2~ and PGF~2α~ and delivered approximately one-half day early \[[@bib80]\]. Consistent with these earlier studies, co-administration of PGE2 and a PGDH inhibitor on gestation day 15 induced birth within 12 to 48 h \[[@bib81]\]. In another study, C3H/HeN inbred wild-type mice treated with 20 μg of PGF~2α~ on 16 dpc delivered 19.3 h postinjection, whereas vehicle-injected mice delivered 53.5 ± 13.6 h postinjection \[[@bib82]\].

Uterine senescence {#sec2-7}
------------------

One hypothesis states that gestation length is governed by the timing of placental and decidual senescence, marked by a reduction in telomere length, and that parturition is initiated when these tissues become "old" \[[@bib83]\]. Cellular aging is promoted by signaling through mammalian target of rapamycin complex 1 (mTORC1). The tumor suppressor p53 reduces mTORC1 signaling by activating AMP kinase, thereby inhibiting the aging process. To examine the relationship between uterine senescence and parturition, mice were generated lacking p53 specifically in the uterus. Once pregnant, these mice had decreased AMP kinase activation and increased mTORC1 signaling, resulting in early decidual senescence and increased incidence of preterm delivery (before 19 dpc) in some females \[[@bib84]\]. Modeling gene--environment interactions, work in this model demonstrated that low-dose LPS injection further increased the incidence of preterm birth \[[@bib87]\].

Uterine quiescence {#sec2-8}
------------------

The protease caspase-3 helps maintain quiescence by cleaving contractile proteins during gestation \[[@bib88]\]. Condon and colleagues hypothesized that caspase-3 is maintained in an active state during pregnancy by the endoplasmic reticulum (ER) stress response and that its activity is reduced by the unfolded protein response at the end of pregnancy. In support of this model, injecting mice with tunicamycin, which induces excessive ER stress response, on 15 dpc caused early increases in levels of the contractile proteins connexin-43, alpha actin, and gamma actin, and resulted in dose-dependent early onset of labor beginning on 16 dpc. Conversely, co-administration of 4-phenylbutrate, an inhibitor of ER stress, prevented both the increase in contractile proteins and preterm birth \[[@bib89]\].

Endocannabinoid signaling pathway {#sec2-9}
---------------------------------

In human pregnancy, levels of the endocannabinoid anandamide are high in early gestation, decrease during mid-gestation, and spike at the onset of labor \[[@bib90], [@bib91]\]. Anandamide is thought to affect parturition timing by controlling secretion of corticotropin-releasing hormone (CRH) \[[@bib92]\], which regulates the duration of pregnancy and onset of labor \[[@bib93], [@bib94]\]. Anandamide and another cannabinoid, 2-arachidonoxylglycerol, signal through the G protein-coupled cannabinoid receptor CB1 \[[@bib95]\]. Deletion of the CB1 gene caused pregnant mice to go into preterm labor, delivering about one-half day before term. In this model, preterm delivery was thought to occur because of early progesterone withdrawal and increased estrogen production during pregnancy. Additionally, signaling through CB1 may control the CRH/corticosterone endocrine axis, as loss of CB1 caused an early rise in CRH and high levels of corticosterone during pregnancy \[[@bib99]\].

Hyperhomocysteinemia {#sec2-10}
--------------------

In a case-control study of 651 women, elevated homocysteine in maternal blood (hyperhomocysteinemia) during pregnancy was associated with increased odds of preterm birth \[[@bib100]\]. One cause of hyperhomocysteinemia is a mutation in the gene encoding cystathionine B-synthase (CBS), an enzyme in the trans-sulfuration pathway \[[@bib101]\]. To test a possible mechanism linking hyperhomocysteinemia to preterm birth, mice were generated carrying a mutation in CBS. CBS^−/−^ pregnant mice had increased blood levels of homocysteine, developed preterm uterine contractions, and delivered significantly early (16.6 dpc vs. 20.2 dpc). Further analysis of this model demonstrated that the contractions were caused by preterm expression of the oxytocin receptor and increased PGE2 synthesis by the enzyme prostaglandin endoperoxide synthase 2 \[[@bib102]\].

Environmental effects: cigarette smoking and dioxin exposure {#sec2-11}
------------------------------------------------------------

Women who smoke cigarettes during pregnancy are at a higher risk of delivering preterm than nonsmokers \[[@bib103]\]. To model this etiology, Ng and Zelikoff exposed mice to cigarette smoke via inhalation between 2 and 18 dpc. The mice exposed to cigarette smoke delivered at 19.6 dpc, whereas unexposed mice delivered at 20.3 dpc; the pups survived in both groups \[[@bib104]\]. A major toxic component of cigarettes is 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin), which is also a ubiquitous environmental contaminant, a by-product of the industrialized process, and an endocrine disruptor. Because animals and humans are most sensitive to environmental toxicant exposure during in utero development, Bruner-Tran and Osteen exposed pregnant mice to dioxin and then examined the effects on fertility and preterm birth in the next two generations \[[@bib105]\]. They found that 36% of females in the F1 generation delivered preterm as adults. Moreover, 25% of the F2 generation (which were exposed as germ cells of the F1 mice in utero) delivered preterm. Furthermore, when F1 females were exposed to GBS, mouse parvovirus, or LPS, the rates of preterm birth increased to 83, 86, and 100%, respectively \[[@bib105], [@bib106]\]. This model suggests that toxicant exposure acts additively with other risk factors to cause preterm birth.

Other models of PTB {#sec2-12}
-------------------

Additional mouse models of preterm birth working through mechanisms of action not discussed above include inhibition of nitric oxide synthesis by treating mice with N^G^-nitro-L-arginine methyl ester \[[@bib107]\]; inhibition of soluble guanylate cyclase by treating mice with methylene blue \[[@bib108]\]; exogenous surfactant protein-A, which initiates the NF-κB-signaling cascade in the uterus \[[@bib109]\]; injection of neuromedin B, which acts through its receptor to induce labor onset via the RELA (NF-κB P65)/IL6-mediated pathway \[[@bib110]\]; and alcohol-induced preterm birth, which is associated with elevated levels of uterine PGE and PGF~2~α and increased expression of contraction-associated proteins and is prevented by pretreatment with the prostaglandin synthesis inhibitor aspirin \[[@bib14], [@bib111]\].

Defining preterm birth in mouse models {#sec3}
======================================

Given the large number of available mouse preterm birth models, standard definitions would allow researchers to appropriately compare results between studies and make meaningful inferences for human preterm birth. We argue that two related questions should be addressed when considering available and newly developed models: (1) Is the gestational length truly shortened, or does delivery occur within the normal range for the mouse strain? (2) Does the model deliver pups that are developmentally immature at delivery? Below, we draw on representative examples listed in Table [1](#tbl1){ref-type="table"} to highlight variations in experimental design that complicate our ability to evaluate and compare the current mouse models of preterm birth.

Strain-specific characteristics {#sec3-1}
-------------------------------

Researchers have used several different strains of mice to generate models of preterm birth. The mouse strain is an important consideration given the findings of Murray et al. that gestational lengths can vary by as much as 41.7 h, or a full 1.72 days \[[@bib16]\]. For example, the FVB/NJ, C57BL/6J, 129S1/SVIMJ, and A/J strains have average gestational lengths of 450.6, 462.4, 486.3, and 492.3 h, respectively, corresponding to between 18.8 and 20.5 days \[[@bib16]\]. Clearly, the strain background has to be considered when determining whether a preterm birth model has shortened gestation.

Approaches for timed matings {#sec3-2}
----------------------------

Comparing gestational lengths between studies is complicated by variations in breeding protocols. For example, whereas most investigators breed mice overnight, some breed for undefined periods of time, and others obtain timed-mated animals from commercial suppliers. Mating strategies should be standardized given that interlitter variability in fetal body weights is greater when mice are bred continuously than when they are mated for 2 h or overnight \[[@bib112]\]. Additionally, our field should standardize the definition of the start of gestation. Investigators record the time at which they see a copulation plug as 0.0, 0.5, or 1.0 dpc. This could result in up to a 24-h difference in timing of gestational length, perhaps leading a delivery to be scored as preterm when it is within the normal variation of delivery time for that mouse strain.

Monitoring the timing of parturition {#sec3-3}
------------------------------------

Multiple methods have been used to monitor the timing of delivery. The onset of parturition is typically defined as the time of delivery of the first pup, which can be precisely determined by using a video camera with infrared lighting to record events in the dark. In contrast, strategies such as checking the dam multiple times during the day and recording the pup number may lead to inaccuracies because newly delivered pups can be hidden in the bedding or may be cannibalized if the dam considers the offspring to be abnormal. Furthermore, mice subjected to frequent disturbances in their cage or a nearby cage may enact a "predator response" defense mechanism that can alter their parturition behavior \[[@bib113]\]. If an investigator checks the dam only on the expected morning of delivery, he or she may not realize that offspring were already delivered and thus may report that gestation was longer than it actually was.

Measures of development {#sec3-4}
-----------------------

Few studies provide comprehensive fetal outcome measurements of their preterm birth models \[[@bib108]\]. Typically, studies report survival of offspring born preterm (Table [1](#tbl1){ref-type="table"}), yet few provide details on the pups\' developmental status (immature or mature).

Proposed guidelines for defining preterm birth in mouse models {#sec4}
==============================================================

For all studies, investigators should be aware that specific animal facility characteristics, such as diets, bedding, water, animal husbandry, co-bedding with other pregnant dams, environment (conventional vs. barrier systems), and noise pollution, could affect gestation length. Thus, instead of relying on published values, investigators should measure and report term gestational length in wild-type, untreated mice in the same facility in which they will do their experiments. Additionally, we suggest the following guidelines in reporting studies of existing and novel mouse models of preterm birth.

Breeding and timing of gestational length {#sec4-1}
-----------------------------------------

Because gestational length varies by mouse strain, it is extremely important to breed controls of the same genetic background when using transgenic models. We suggest two methods of breeding:

### Timed breeding {#sec4-1-1}

One of the most accurate methods for estimating gestational length is to restrict the mating period \[[@bib112]\]. Because hormonally receptive females usually mate within 1 h \[[@bib114]\], pairing estrus-stage females with males for 2 to 4 h and then checking for the presence of a copulation plug allows for accurate assessment of gestational length. Alternatively, multiple breeding cages of unstaged females can be set up for a restricted time. The time at which the copulation plug is noted should be recorded as 0.0 dpc, and the following morning should be considered 0.5 dpc. We recommend caution in using timed-mated mice in preterm birth studies provided by a commercial supplier, as gestational length is likely to be affected by shipping, handling of the mice, potential quarantine, temperature changes, and alterations in light--dark cycles.

### Overnight breeding {#sec4-1-2}

When mice cannot be bred for a restricted time period or less precision is acceptable, mice can be bred overnight. Place estrus-stage dams with stud males overnight, and check for the presence of a copulation plug before 8:00 am the next day. This method is effective because fertilization occurs around midnight, or the mid-point of the active period, in a 12-h dark/light cycle \[[@bib115]\]. Thus, the time at which the plug is noted should be recorded as 0.5 dpc. Transgenic facilities commonly use this method and find that the majority of fertilized eggs harvested the morning after overnight mating are at the 0.5 dpc stage. This method will allow investigators to assign the time of conception (and thus the length of gestation) within a 12- to 18-h window.

Monitoring pregnancy outcomes {#sec4-2}
-----------------------------

### Timing and delivery complications {#sec4-2-1}

The most precise and efficient way to monitor delivery is to use an infrared video camera system. This allows an investigator to observe delivery of the first pup (which should be defined as the end of gestation), total duration of parturition, and subtle phenotypes such as dystocia, which can be ascertained by measuring the pup-to-pup interval (which averages 15 min for C57Bl/6; unpublished data). This method also allows detection of delivery even if the dam cannibalizes her litter.

### Delivery outcomes {#sec4-2-2}

To establish a new model of preterm birth or validate an existing one, several informative characteristics should be recorded for each delivery: (1) litter size, because of the strong inverse correlation with gestational length \[[@bib16], [@bib116]\]; (2) offspring mortality rate, because any increase may indicate death related to prematurity; (3) pup crown-rump length \[[@bib117]\]; and (4) pup weight. However, these characteristics are not definitive indicators of prematurity and may vary by strain. Lastly, we suggest use of reliable fetal growth markers that, preferably, are relevant to human fetal development. We describe two classes of such markers, involving skin and the lungs, in the next section.

Mouse fetal development markers {#sec4-3}
-------------------------------

Here, we suggest two straightforward methods to assess fetal tissue maturation. The Institutional Animal Care and Use Committee at each respective institution approved all protocols performed for this review.

### Skin barrier function {#sec4-3-1}

The skin forms a permeability barrier that regulates body temperature, prevents excess water loss, and prevents invasion by harmful pathogens. In humans, the epithelium fully develops its barrier function by late gestation (∼34 weeks) \[[@bib118]\]. Therefore, infants born before 30 weeks\' gestation are at increased risk for infection and loss of temperature and fluid \[[@bib119], [@bib120]\]. The barrier develops when the outer layer of the epidermis forms the stratum corneum, which is composed of a tough insoluble cornified envelope that is "glued" together by a complex extracellular lipid matrix \[[@bib121]\]. Barrier function develops similarly in mice late in gestation, beginning at 17 dpc and developing in a dorsal-to-ventral pattern until birth, when the barrier is fully formed. Thus, assessment of barrier function can indicate developmental stage of pups.

### Methods to assess skin barrier maturation {#sec4-3-2}

Barrier function can be assessed by performing a whole-mount skin permeability assay as previously reported \[[@bib122]\]. To perform this assay, dissect pups from the dams on the day of delivery, place them in a solution containing the blue dye 5-bromo-4-chloro-3- indolyl-β, D-galactopyranoside (X-gal), and gently nutate for 8 h to overnight at 37°C \[[@bib122]\]. Wash samples twice with phosphate-buffered saline, fix overnight in 4% formaldehyde at 4°C, and store in phosphate-buffered saline at 4°C. Evaluate pups for blue dye penetration. Figure [1](#fig1){ref-type="fig"} shows examples of pups at different gestational stages subjected to this assay. For C57Bl6/J mice at 17 dpc, the skin barrier is immature and fetuses are uniformly blue. By 18 dpc, the skin on the dorsal side starts to cornify and becomes impermeable to the dye and is thus white, while the ventral side is still permeable and thus is blue. By late 18 to 19.0 dpc, the skin barrier has fully formed and the skin is impermeable to the dye, so the pup is almost completely white.

![Skin permeability as a marker of maturity. In C57BL/6 mice, dye permeated mice at 17.0 dpc. By 18.0 dpc, dye was excluded on the dorsal side, but the pup remained blue on the ventral side. By 19 dpc, the skin was impermeable and faint blue stain was only noted on the ventral side. (Please see the online version for the color figure.)](ioy109fig1){#fig1}

Skin maturation can also be assessed histologically \[[@bib123]\]. To perform this assay, fix fetuses in 10% formalin, dehydrate them through an ethanol series, embed them in paraffin, cut 8 μm sections, mount the sections on glass slides, and perform routine hematoxylin and eosin (H&E) staining. Examine the skin for markers of maturation including thickness, stratification of the epidermal and dermal papillary layers, and hair follicle density. As shown in Figure [2](#fig2){ref-type="fig"}, skin samples from 17 dpc pups have thin epidermal and dermal papillary regions and contain few hair follicles. In contrast, skin samples from 19 dpc pups have thick, stratified epidermal layers and thick papillary regions and contain multiple hair follicles.

![Skin histologic changes during gestation. In whole mount, the skin of 17 dpc CD-1 fetuses appeared more translucent (**A**) than that of 19 dpc fetuses (**C**). H&E-stained sections of dorsal skin from 17 dpc fetuses had thinner epidermal (**E**) and dermal papillary (DP) layers and contained fewer hair follicles (asterisks) than H&E-stained sections of skin from 19 dpc fetuses (**B** and **D**). (Please see the online version for the color figure.)](ioy109fig2){#fig2}

### Lung maturity markers {#sec4-3-3}

Lung development proceeds through markedly similar steps in mammals \[[@bib124], [@bib125]\]. This process begins with branching morphogenesis, in which the embryonic tracheal lung bud reiteratively branches to form large and small airways \[[@bib126]\]. Branching morphogenesis is complete by mid-gestation in humans and mice and is followed by a period of mesenchymal thinning and epithelial differentiation. Finally, the lungs become alveolarized, during which alveolar septation expands the gas exchange structures of the lung \[[@bib127]\]. In humans, this process begins at 36 weeks\' gestation and continues into early childhood \[[@bib128], [@bib129]\]. In mice, alveolarization occurs entirely postnatally, beginning at postnatal day 4--5 and becoming fully mature by postnatal day 30. We describe two methods that can be used to assess the extent of lung mesenchymal thinning and epithelial differentiation as a marker of fetal maturity in mice \[[@bib130]\].

### Morphometric assessment of lung maturation {#sec4-3-4}

Morphometric assessment of lung airspaces reveals the degree of mesenchymal thinning that occurs after branching morphogenesis is complete and before alveolarization initiates. To evaluate lung morphology, dissect out fetal lungs, section them, H&E stain the sections, and view the lung sections at ×40 magnification (Figure [3A and B](#fig3){ref-type="fig"}). Avoid fields containing large vessels or airways. Use computer-assisted morphometry (e.g. Image-Pro Plus software; Media Cybernetics) to count the number of airspaces and measure airspace diameter and airspace perimeter. Calculate airspace volume density by dividing the sum of the airspace area by the total area (Figure [3C--F](#fig3){ref-type="fig"}). In our experience, the airspace perimeter is the least reliable measure of lung maturity because airspace shape becomes more variable as the mesenchyme thins \[[@bib131]\].

![Lung morphometry as a marker of lung maturity. H&E stained lungs from 17 and 19 dpc CD-1 mouse fetuses (**A, B**). Lung morphometry measurements indicated that, compared to 17 dpc lungs, 19 dpc lungs contained more airspaces (**C**), had larger airspace volume density (airspace area divided by total lung area) (**D**), and had larger airspace diameter (**E**). However, airspace perimeter was similar in the two groups (**F**). n = 6 for both 17 and 19 dpc; \**P*-values, calculated by t-test; error bars represent SEM. (Please see the online version for the color figure.)](ioy109fig3){#fig3}

### Protein and mRNA markers of lung epithelial differentiation {#sec4-3-5}

Infants born prematurely, especially at \<34 weeks\' gestation, have pulmonary complications due to lung immaturity, and those infants that survive are at increased risk for long-term adverse pulmonary outcomes such as asthma, reduced lung function, and chronic lung disease \[[@bib2], [@bib5]\]. These pulmonary deficits are due, in part, to insufficient lung surfactant, composed of lipids and proteins that are secreted by fully differentiated type 2 alveolar epithelial cells. Surfactant reduces surface tension, helps maintain normal lung volumes, and is essential for normal breathing \[[@bib132]\]. The four major protein components of surfactant are surfactant proteins B and C (SP-B and SP-C), which interact with phospholipids to improve surfactant dispersion at the air/liquid interface and prevent alveolar collapse \[[@bib130], [@bib133]\], and surfactant proteins A and D (SP-A and SP-D), which act as part of the innate immune system by opsonizing bacteria for clearance by pulmonary macrophages.

In mice, SP-A is expressed in the fetal lung late in gestation, becoming detectable in the amniotic fluid by 17.0 dpc and maximally expressed by 19.0 dpc \[[@bib109]\]. Fetal SP-A is a particularly interesting marker of gestational lung maturity because it appears to help initiate parturition. Thus, detection of SP-A mRNA or protein in fetal lung or amniotic fluid could be used as a marker for fetal maturity in mice \[[@bib109], [@bib134]\]. SP-B, which is clinically administered to premature babies to treat surfactant deficiency, can likewise be used as a fetal lung marker. As shown in Figure [4A](#fig4){ref-type="fig"}, SP-B mRNA increases in the fetal lung by up to 5-fold between 17 and 19 dpc and by up to 10-fold at postnatal day 1. SP-C, a transmembrane protein expressed exclusively in alveolar type 2 cells postnatally, can similarly be used as a marker of lung maturity (Figure [4B](#fig4){ref-type="fig"})\[[@bib135]\].

![Gene expression as a marker of lung maturation. RNA isolated from pups of the indicated gestational ages was reverse transcribed to produce cDNA (SuperScript VILO kit; Invitrogen), and multiplex quantitative PCR reactions were performed with a StepOnePlus PCR System (Applied Biosystems) using the following FAM-labeled TaqMan Gene Expression assays (Applied Biosystems): SP-B Mm00455679_m1, ENac Mm00803386_m1, Aqp5 Mm00437578_m1, SP-C Mm00488144_m1, and Nkx2.1 Mm00447558_m1. The VIC-labeled housekeeping gene, 18S, was used as an internal control. Triplicate ΔΔCT values were generated for each sample. mRNA levels relative to dpc 17 mRNA were calculated by using the equation FC = 2^−ΔΔCT^. n = 4 for each timepoint; \**P*-values, calculated by one-way ANOVA with Dunnett post hoc analysis, denote comparisons between indicated values and 17 dpc values; error bars represent SEM.](ioy109fig4){#fig4}

Two other proteins that can be used as markers of lung development are the water channel Aquaporin 5, which is expressed in alveolar type 1 cells and is thought to facilitate fluid absorption in the perinatal lung \[[@bib136]\], and the epithelial sodium ion channel (ENaC). Two of the three ENaC subunits increase sharply in the mouse fetal lung at late gestation \[[@bib137]\]. As seen in Figure [4C and D](#fig4){ref-type="fig"}, mRNA expression of ENaC and Aquaporin 5 increase in late gestation and can be used as markers of fetal lung maturity \[[@bib135]\].

In addition to the above markers, panels of 50 or more genes have been evaluated as markers of fetal lung maturity in mice \[[@bib130]\]. However, due to differences in mouse strain, detection methods, and reagents (primary antibodies, PCR primers), some of these proteins/genes may not be reproducible markers. For example, we found that NK2 Homeobox *1* (*Nkx2.1)*, an epithelial transcription factor critical for embryonic lung morphogenesis, was expressed at similar levels in 17 dpc, 19 dpc, and postnatal day 1 lungs. Therefore, we recommend that investigators evaluate multiple lung maturation markers. In addition, absolute levels of each marker are not sufficient to assess lung maturity and should always be compared to levels in full-term pups of the appropriate genotype and strain.

Conclusion {#sec5}
==========

Researchers have used several mouse models to test hypotheses regarding preterm birth. These include models of genetic, infectious, noninfectious (sterile) inflammatory, environmental toxins, and endocrine etiologies. However, comparing data between studies is challenging given the lack of uniform criteria for defining preterm birth and assessing pup maturity. A recent review by Manuel et al. encourages investigators to develop better mouse models that are more consistent with the human etiologies of preterm birth \[[@bib138]\]. In this review, we recommend that our field adopt standardized experimental and reporting guidelines to define preterm birth and use fetal developmental markers to distinguish between premature and mature pups. In addition to the skin and lung markers proposed here, we welcome other easy-to-use developmental markers. By standardizing our methods and reporting, mice should become an even more valuable model with which to study the important problems of preterm birth and the resulting neonatal co-morbidities.
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